Mylan launches generic bronchospasm treatment

PITTSBURGH Generic drug maker Mylan has launched a version of a drug used to treat bronchospasm.

The Pittsburgh-based company announced Tuesday the launch of levalbuterol inhalation solution in the 0.25% strength. As the first company to file for Food and Drug Administration approval for the drug, Mylan will get six months of market exclusivity in which to compete directly with the branded product.

The drug is a generic version of Sepracor’s Xopenex, which had sales of $18.3 million for the 12 months ending June 30, according to IMS Health data. The drug is approved for treating and preventing bronchospasm in patients older than 6.